MobbleOpen in Mobble ⇢
Health · Drug development · published 2026-09-26 · via BiopharmaWatch

FDA Approves Atebrioz for FOP Patients Aged 12 and Older

Image via BiopharmaWatch
Image via BiopharmaWatch

Mirum Pharmaceuticals and Incyte said the U.S. FDA has approved Atebrioz (zilurgisertib) tablets. The drug is intended to reduce the total volume of new heterotopic ossification in adults and children aged 12 and older with fibrodysplasia ossans progressiva.

Expanded Detail

Mirum Pharmaceuticals and Incyte said the FDA has cleared Atebrioz (zilurgisertib) tablets for use in the United States. The approval covers adults and pediatric patients aged 12 and older who have fibrodysplasia ossificans progressiva.

The drug's intended effect is to lower the amount of newly developing heterotopic ossification. Mirum is based in Foster City, California, while Incyte is based in Wilmington, Delaware; both companies are publicly traded on Nasdaq.

Context

For people with FOP and their families, this approval may offer a new option aimed at slowing new abnormal bone formation, potentially reducing disease burden and need for care. Clinicians could gain another tool for patients aged 12 and older. Access, affordability, and long-term outcomes may shape real-world impact, and broader awareness of this rare condition could grow.

Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Read the full article at BiopharmaWatch →
Related stories
Mirum and Incyte Secure FDA Approval for Atebrioz in FOP · Drug development
Atebrioz Gains FDA Clearance for Adult and Pediatric FOP · Drug development
FDA clears Mirum’s ALK2 inhibitor for ultra-rare genetic disorder · Drug development
FDA Approves Targeted Therapy for FGFR2-Altered Cholangiocarcinoma · Drug development
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Samenvatting: Mirum Pharmaceuticals en Incyte maken bekend dat de Amerikaanse FDA goedkeuring heeft verleend voor Atebrioz™ (zilurgisertib) voor volwassen en pediatrische patiënten met fibrodysplasia ossificans progressiva.” Browse more stories.